Compass Pathways Plc (CMPS)
11.62
+0.35
(+3.11%)
USD |
NASDAQ |
Oct 15, 16:00
11.63
+0.01
(+0.09%)
After-Hours: 20:00
Compass Pathways Research and Development Expense (Quarterly) : 29.23M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 29.23M |
| March 31, 2026 | 26.44M |
| December 31, 2025 | 29.86M |
| September 30, 2025 | 27.15M |
| June 30, 2025 | 30.70M |
| March 31, 2025 | 31.00M |
| December 31, 2024 | 31.84M |
| September 30, 2024 | 33.27M |
| June 30, 2024 | 29.10M |
| March 31, 2024 | 24.89M |
| December 31, 2023 | 27.38M |
| September 30, 2023 | 21.40M |
| June 30, 2023 | 19.88M |
| Date | Value |
|---|---|
| March 31, 2023 | 19.21M |
| December 31, 2022 | 19.94M |
| September 30, 2022 | 13.86M |
| June 30, 2022 | 15.78M |
| March 31, 2022 | 15.27M |
| December 31, 2021 | 13.61M |
| September 30, 2021 | 12.14M |
| June 30, 2021 | 11.33M |
| March 31, 2021 | 6.908M |
| December 31, 2020 | 4.544M |
| September 30, 2020 | 6.875M |
| June 30, 2020 | 6.724M |
| March 31, 2020 | 5.226M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Silence Therapeutics Plc | 8.297M |
| Biodexa Pharmaceuticals Plc | -- |
| NuCana Plc | 3.020M |
| Mereo BioPharma Group Plc | 1.811M |
| HemoGenyx Pharmaceuticals Plc | -- |